Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

Buy-and-Bill

COVID-19

Case-Based Roundtable

Chronic Hand Eczema

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Perspectives in Dermatology

Polls

Editorial Advisory Board

Partners

Subscribe

Marie Bosslett is the assistant editor of 

 and joined the MJH Life Sciences team in October 2024. She attended Loyola University Maryland in Baltimore and earned a Bachelor of Arts in Communication with minors in marketing and writing. When she’s not writing, Marie enjoys going to concerts, reading on the beach, and spending time with friends and family.

Articles

As newly appointed Executive Director of the Foundation, Becky Kamowitz is combining public education with clinical needs in the fight against skin cancer.

Q&A with Becky Kamowitz of the Skin Cancer Foundation: Expanding Partnerships and Advancing Awareness in 2025

Kaitlyn Bader is the assistant managing editor of 

 and joined the MJH Life Sciences team in June 2022. She attended Otterbein University in Westerville, Ohio, and earned a Bachelor of Arts degree in literary studies with minors in creative writing and film studies. Prior to health care news, Kaitlyn worked in industrial marketing. She enjoys cooking, reading, and tending to her house plants.

Pilot and research grants may be awarded to research on keratinocyte biology and differentiation, genetics, biology of skin inflammation, itch, or other ichthyosis-related areas. 

 Foundation for Ichthyosis & Related Skin Types Now Accepting Letters of Intent for 2025 Research Grant Program 

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and is now finishing her Masters in Digital Media through Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family.

In an interview with Dermatology Times, Del Rosso shared the latest in the treatment landscape for patients with Darier disease.

What’s New in the Medicine Chest: Darier disease

Learn more about the in-depth topics covered in the January 2025 print issue of Dermatology Times.

Dermatology Times January 2025 Print Recap

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

Authors

Miller, Vice President, Immunodermatology Disease Area Leader, Johnson & Johnson, spoke with Dermatology Times about recently published data supporting JNJ-2113's potential in this indication.

Lloyd Miller, MD, PhD: Delving Into JNJ-2113 Data for Plaque Psoriasis

Final Thoughts: The Importance of Comparative Studies in AD

Panelists offer concluding insights and emphasize the critical role of comparative studies in advancing atopic dermatitis treatment strategies.

clinical

Video Series

To stay up-to-date with the latest dermatology news, sign up to receive our 

Dermatology Conferences and Meetings Calendar: 2025

 has asked our readers to share with us what conferences and meetings they are looking forward to or planning to attend in 2025. Using these responses, we have compiled a list of dermatological meetings taking place this year.

DFD-29: The Journey to FDA Approval and a New Era in Rosacea Management

The FDA approval in November 2024 of 40-mg minocycline hydrochloride (Emrosi; Journey Medical Corporation), formerly known and hereafter referred to as DFD-29, marked a significant step forward in the treatment of rosacea.

The approval of these 40-mg extended-release capsules represents the first time an oral, systemic therapy has been given the green light in the US to address both erythema and inflammatory lesions—2 hallmark symptoms of rosacea. Here, 

 looks back at DFD-29’s journey to approval and its future role in the rosacea treatment landscape.

Hair care is, without a doubt, the trendiest of all areas of dermatology! Because hair is nonliving, it does not fall under any governmental regulation, so creativity is the name of the game, and the wilder the better. However, the rapidly changing hair care market is important to the dermatologist, because we are indeed the hair experts. To keep you abreast of hair care trends, Zoe Diana Draelos, MD, examined 3 of the most popular hair care ideas for 2025.

The Unprecedented Phase 1 Results of ET-02 for the Treatment of Androgenic Alopecia

Eirion Therapeutics announced positive results for its first-in-man clinical trial of topical ET-02 in the treatment of androgenic alopecia. The drug was safe and well-tolerated, with unprecedented results being observed as early as 5 weeks.

Jon Edelson, MD, CEO of Eirion, confirms that topical ET-02 is a completely new approach to treating this type of hair loss.

 spoke with Jon Edelson, MD, CEO and President of Eirion. He shared groundbreaking insights into the therapeutic potential of ET-02, its mechanism of action, and how it aims to revolutionize the treatment landscape for hair loss.

Expanding NP and PA Opportunities in Dermatology Practice

At the inaugural Horizons in Advanced Practice meeting, Douglas DiRuggiero, DMSc, MHS, PA-C, discussed how NPs and PAs can advance their professional growth by seizing opportunities to share their clinical experiences.

DiRuggiero, a dermatology physician assistant (PA) with 25 years of experience in medical and surgical dermatology, shared insights from his experience as a cochair of Horizons in Advanced Practice. 

Expanding NP and PA Opportunities in Dermatology Practice 

“Include us in ad boards. Include us in publishing. Include us in poster creation. We want to be able to do all the things that our MD counterparts are doing. We’re not trying to be them, but we want to rub shoulders with them. We want to have the same chances to grow professionally that they have,” DiRuggiero said in an interview with 

 at the meeting held in Las Vegas, Nevada.

The recent developments in dermatology include the FDA approval of DFD-29, a novel oral therapy for rosacea, marking a significant advancement in managing erythema and inflammatory lesions. Eirion Therapeutics' ET-02 shows promising Phase 1 results for androgenic alopecia, potentially revolutionizing hair loss treatment. The expanding roles of NPs and PAs in dermatology were highlighted at the Horizons in Advanced Practice meeting, emphasizing their desire for professional growth opportunities. Additionally, the dermatology community is keenly observing emerging hair care trends and upcoming conferences in 2025.

Explore the top headlines of the week including clinical trial updates, social media hair trends, and expert insights.

Top 5 Articles of the Week: January 19-24

According to new data, dupilumab is confirmed to be safe and effective for Chinese patients with moderate to severe refractory PN.

 This is the largest multicenter real-world study for dupilumab in China, fulfilling a previously unmet need in this PN patient population.

The multicenter, observational study was held across 10 hospitals in China. All 73 participants (33 female and 40 male) were treated between July 2023 and January 2024. The sample was also further divided into subgroups by age with 12 pediatric patients, 38 adults, and 23 elderly patients (≥ 60 years old). The cohort had a mean age of 45.9 years with a median disease duration of 3 years.

Eligible participants had a mean peak pruritus numeric rating scale (PP-NRS) ≥ 7 with at least 20 PN legions. These patients were also resistant to and dissatisfied with conventional therapies like topical or systemic corticosteroids and immunosuppressants. All patients received an initial 600 mg subcutaneous injection and then 300 mg dosages every 2 or 4 weeks thereafter, depending on weight. The follow-up period lasted at least 16 weeks with disease severity scores being reported every 2 weeks.

Participants were assessed using the PP-NRS, investigator global assessment (IGA) for PN, and dermatology life quality index for adults or children (DLQI/CDLQI). At baseline, the mean PP-NRS score was 7.9 and the average DLQI/CDLQI score was 16.6. All patients had an IGA score of 3 or 4, with the least number of nodules being 20 and the most being ≥ 100.

Nearly 85% of patients saw an improvement of ≥ 4 points in PP-NRS at week 12. Also in week 12, 37% achieved an IGA score of 0/1. This improved to 46.6% at week 6, equating to a response of “clear” or “almost clear” skin with a reduction to ≤ 5 nodules. These positive results mirror what was observed in previous phase 3, single-center clinical trials.

Quality of life outcomes also improved substantially, decreasing from 16.6 at baseline to 7.2 at week 12 and 6.4 at week 16. Furthermore, time-effect relationship results in all categories confirmed the fast-acting nature of dupilumab to relieve itch and improve quality of life.

There were no statistically significant differences between the 3 age groups in terms of achieving IGA 0/1, indicating that the treatment worked well among all ages. Additionally, there was no difference in baseline severity and effectiveness in the 36 participants with atopic PN versus those without. Regarding adverse effects, only 1 patient reported dry eyes after the first injection and found relief with an artificial tear solution. This confirms dupilumab’s favorable safety profile.

Potential selection bias and small sample size of pediatric patients may be considered possible limitations of the study. There was also a limited number of recorded laboratory results with different reference ranges depending on the center, which could impact the analysis.

“There is no ‘one fits all’ therapy, so not all PN patients show an optimal response to dupilumab,” the authors wrote. “Therefore, predictors of response and mechanisms of dupilumab in PN await extensive exploration in the future.”

However, this literature addresses the previous gap in research regarding dupilumab’s safety and effectiveness in Chinese patients. Although dupilumab has been approved for PN, only a small number of Asian patients were included in the phase 3 clinical study.

“Our results redemonstrate the heavy burden of PN,” the authors concluded. “Despite previous topical and systemic therapies, especially high usage of off-label drugs, the patients had a poor disease control and dissatisfaction for treatment at baseline, which reveals a huge unmet need for treatment of PN in China, indicating a strong need for effective therapy.”

1. Zhao Z, Song X, Shang Y, et al. Effectiveness and Safety of Dupilumab for Prurigo Nodularis in China: A Multicentric and Observational Study. 

Published online January 21, 2025. doi:10.1111/all.16478

2. Yosipovitch G, Mollanazar N, Ständer S, et al. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials.

2023;29(5):1180-1190. doi:10.1038/s41591-023-02320-9

Dupilumab has been validated as a safe and effective treatment for Chinese patients with moderate to severe refractory prurigo nodularis (PN) through a large multicenter real-world study. Conducted across 10 hospitals, the study involved 73 participants, including pediatric, adult, and elderly patients. Significant improvements were observed in pruritus and quality of life scores, with no major age-related differences in treatment efficacy. The study highlights dupilumab's rapid action and favorable safety profile, addressing a critical unmet need in PN treatment in China, despite potential limitations like selection bias and small pediatric sample size.

85% of Chinese PN patients saw a PP-NRS improvement of ≥ 4 points after 12 weeks of treatment.

Real-World Data Supports Dupilumab for Prurigo Nodularis Treatment in China

Hyperhidrosis is not rare. According to the 

, approximately 385 million people worldwide live with hyperhidrosis.

In fact, they note that the amount of people living with chronic, excessive sweating is even higher than the amount of people living with other dermatologic conditions like psoriasis.

Just how common is hyperhidrosis in real-world comparisons?

The prevalence of hyperhidrosis is much higher in younger populations than in the general population, with 8.8% of individuals between the ages of 18 to 39 years old living with the condition. 

When comparing these statistics to everyday, common occurrences like hair color, the number of people with hyperhidrosis is greater than the 1% of individuals with natural red hair and 2% of individuals with natural blond hair. 

Despite how common hyperhidrosis is, it is estimated that 27% of those with the condition never receive a diagnosis.

 wants to hear from you. What percentage of the global population is estimated to have hyperhidrosis?

 to share your hyperhidrosis insights or research.

Albert. Fact check: Hyperhidrosis - International Hyperhidrosis Society: Official site. Home - International Hyperhidrosis Society. October 24, 1970. Accessed November 16, 2023. 

https://www.sweathelp.org/home/news-blog/542-fact-check-hyperhidrosis.html

Hyperhidrosis affects approximately 385 million people globally, surpassing the prevalence of other dermatologic conditions like psoriasis. It is notably more common in younger populations, with 8.8% of individuals aged 18 to 39 experiencing the condition. Comparatively, hyperhidrosis is more prevalent than natural red or blond hair, which affects 1% and 2% of the population, respectively. Despite its prevalence, 27% of those with hyperhidrosis remain undiagnosed. The article encourages engagement during Hyperhidrosis Awareness Month to share insights and research on the condition.

Click here to answer this week's poll for Hyperhidrosis Awareness Month.

Polls 

POLL: What Percent of the Global Population is Estimated to Have Hyperhidrosis?

The 2022 Annual Society of Dermatology Nurse Practitioners (SDNP) Symposium is happening this weekend, April 22 to 23, in Nashville, Tennessee at the Gaylord Opryland. This third edition of the event is in person and will feature a certification review course on April 24 and 25.

This event will have sessions on important topics such as immunology, dermatoses, hair disorders and more. It will also feature morning exercises, line dancing, and other networking opportunities. Not to mention the chance to have a headshot taken between the 2 days.

This meeting is specifically aimed at dermatology nurse practitioners (NPs) and offers them the support and knowledge they need to excel in the field. To learn more about the symposium please visit their website, 

Sdnp 2022 annual symposium. Accessed April 20, 2022. https://www.dermnp.org/sdnp-2022-annual-symposium_

The 2022 Annual Society of Dermatology Nurse Practitioners Symposium is taking place in Nashville, Tennessee, from April 22 to 23, with a certification review course on April 24 and 25. This in-person event will cover key topics such as immunology, dermatoses, and hair disorders, alongside networking activities like morning exercises and line dancing. Aimed at dermatology nurse practitioners, the symposium provides essential support and knowledge to advance in their field. Attendees can also have professional headshots taken during the event.

The Society of Dermatology Nurse Practitioners is having its annual conference this weekend, starting April 22 through 23 with a certification review course happening April 24 to 25, in Nashville, Tennessee. 

Starting Off the SDNP Conference

In this video interview, Andrew Blauvelt, MD, MBA, dermatologist and clinical researcher at the Oregon Medical Research Center, explains the biggest moves in psoriasis that everyone in the health care field needs to know.

In this video interview, Andrew Blauvelt, MD, MBA, dermatologist and clinical researcher at the Oregon Medical Research Center, highlights his key takeaways from his presentation at the Annual Society of Dermatology Nurse Practitioners Symposium, held April 22-23, in Nashville, Tennessee. 

Lloyd Miller, MD, PhD

Articles

Latest Updated Articles